Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2015 01:09 ET | Source: Vifor Pharma Ltd.

Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS in Europe and additional territories

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} ST....
May 28, 2015 01:11 ET | Source: Vifor Pharma Ltd.

Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Galenica...
January 27, 2015 01:15 ET | Source: Vifor Pharma Ltd.

Velphoro® a reçu l'autorisation de mise sur le marché de Swissmedic pour le traitement de l'hyperphosphatémie chez les patients adultes atteints d'insuffisance rénale chronique et placés sous dialyse

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Velphoro® (oxyhydroxyde de fer (III)...
January 27, 2015 01:15 ET | Source: Vifor Pharma Ltd.

Velphoro® erhält die Swissmedic Zulassung zur Behandlung der Hyperphosphatämie bei dialysepflichtigen erwachsenen Patienten mit chronischer Niereninsuffizienz

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Velphoro® (Polynukleares...
September 16, 2014 01:15 ET | Source: Vifor Pharma Ltd.

Vifor Pharma appoints heads of International Business Operations and Global Marketing

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor...
September 02, 2014 06:52 ET | Source: Vifor Pharma Ltd.

CONFIRM-HF study demonstrates that Injectafer(r) (Ferinject(r)) improves exercise capacity in patients with chronic heart failure

Glattbrugg, Switzerland, Sept. 2, 2014 (GLOBE NEWSWIRE) -- The CONFIRM-HF study was designed to compare the efficacy and safety of iron therapy with Injectafer® (US brand name of Ferinject®,...
September 02, 2014 06:50 ET | Source: Vifor Pharma Ltd.

CONFIRM-HF study demonstrates that Injectafer® (Ferinject®) improves exercise capacity in patients with chronic heart failure

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The...
September 01, 2014 01:16 ET | Source: Vifor Pharma Ltd.

CONFIRM-HF study demonstrates that Ferinject® improves exercise capacity in patients with chronic heart failure

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The...
August 27, 2014 01:10 ET | Source: Vifor Pharma Ltd.

Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Velphoro®...
June 27, 2014 08:57 ET | Source: Vifor Pharma Ltd.

Velphoro® recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Velphoro®...